研报掘金丨中银证券：维持昆药集团“买入”评级，看好公司长期发展

Core Viewpoint - The report from Zhongyin Securities indicates that Kunyu Group's net profit attributable to shareholders for the first three quarters reached 269 million yuan, a year-on-year decrease of 39.42%, with a third-quarter net profit of 71 million yuan, down 59.03% year-on-year [1] Group 1: Financial Performance - Kunyu Group's net profit for the first three quarters was 269 million yuan, reflecting a 39.42% decline compared to the previous year [1] - The net profit for the third quarter alone was 71 million yuan, showing a significant year-on-year decrease of 59.03% [1] Group 2: Business Strategy and Outlook - The company is facing sales pressure due to channel adjustments and is looking forward to improved performance in the coming year [1] - Kunyu Group is enhancing collaboration with China Resources Sanjiu, focusing on the silver economy sector, and is committed to strengthening this partnership [1] - The company is accelerating the integration of offline pharmacies and adapting to online purchasing trends, aiming to build a more efficient business model [1] - Efforts are being made to upgrade the "Kunzhong Medicine" brand and to preheat new product series, with the goal of optimizing inventory, improving sales, and enhancing brand communication [1] - The company is increasing its R&D investment and has a deep layout in the chronic disease sector, which supports a positive long-term development outlook [1]